Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 24;10(4):e003472. doi: 10.1136/jitc-2021-003472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

T_RM cells as a tool for GI cancers immunotherapy. T_RM cells are emerging as long persisting potent cytotoxic T cells destined for tissue residency, making them a hot target for cancer immunotherapy in general and GI cancers in particular. This is a representation of the potential therapeutic strategies where T_RM cells could be incorporated into GI cancers standard treatment paradigms. For immune infiltrated or the so-called ‘hot’ GI tumors, T_RM cells could serve as a predictive factor as well as a target for checkpoint inhibitors. For the therapeutically challenging ‘cold’ GI tumors, in vitro expanded or generated CXCR6⁺ tumor-specific T_RM cells could be adoptively transferred in combination or not with checkpoint inhibitors. GI, gastrointestinal; T_RM, tissue-resident memory T cells.